NCT02008227 · OUTCOME

Percentage of Participants Who Died: PP-ITT

A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy · Source last updated 2019-12-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Percentage of Participants
Interval / dispersion: Not reported
Time frame: Baseline until death due to any cause (up to approximately 2.25 years)

Analysis population: PP-ITT analysis set included the first 850 randomized ITT participants regardless of whether they received any study drug.

Groups in this outcome

Docetaxel

Docetaxel 75 milligrams per square meter (mg/m\^2) was administered intravenously (IV) on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.

Atezolizumab

Atezolizumab 1200 mg was administered IV on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Docetaxel	425
Atezolizumab	425

Reported measurements

Source class 1

Values in Percentage of Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Docetaxel	70.1	Not reported	Not reported	Not reported	Not reported
Atezolizumab	63.8	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
70.1
group Id
OG001
value
63.8

denoms

counts
group Id
OG000
value
425
group Id
OG001
value
425
units
Participants

groups

description
Docetaxel 75 milligrams per square meter (mg/m\^2) was administered intravenously (IV) on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.
id
OG000
title
Docetaxel
description
Atezolizumab 1200 mg was administered IV on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.
id
OG001
title
Atezolizumab

param Type

NUMBER

population Description

PP-ITT analysis set included the first 850 randomized ITT participants regardless of whether they received any study drug.

reporting Status

POSTED

time Frame

Baseline until death due to any cause (up to approximately 2.25 years)

title

Percentage of Participants Who Died: PP-ITT

type

PRIMARY

unit Of Measure

Percentage of Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice